Lupus Nephritis Market Size Forecasted To Achieve $2.8 Billion By 2029 With Steady Growth

The Lupus Nephritis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Lupus Nephritis Market Size and Projected Growth Rate?
The market for lupus nephritis has seen robust growth in the past few years and is predicted to expand from $1.94 billion in 2024 to $2.09 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.9%. The growth from the past period is primarily driven by increased investment in lupus nephritis research, a rise in the number of autoimmune disorders, increasing healthcare costs, a growing trend of biologics, and a rising interest in telemedicine.

Anticipations are high for a robust expansion of the lupus nephritis market in the coming years. The market is projected to escalate to $2.80 billion by 2029, with a compound annual growth rate (CAGR) of 7.6%. The growth expected in the forecast period can be credited to factors such as enhanced physician cognizance, rising acceptance of biologic treatments, growth in the number of specialized clinics, the heightened significance of kidney transplants, and enlarged accessibility to nephrology services. Notable trends anticipated during the forecast period encompass breakthroughs in biologic treatments, tailoring of medical treatments, innovative diagnostic biomarkers, wider involvement in clinical trials, and advancements in stem cell therapy methodologies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22044

What Are the Major Segments in the Lupus Nephritis Market?
The lupus nephritis market covered in this report is segmented -

1) By Stage: Class 1, Class 2, Class 3, Other Stages
2) By Drug Class: Immunosuppressive Drugs, Corticosteroids, Biological Agents, Antimalarial Drugs
3) Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Class 1: Asymptomatic Cases, Mild Proteinuria, Incidental Diagnosis.
2) By Class 2: Mild Hematuria, Low-Grade Proteinuria, Minimal Immune Complex Deposition.
3) By Class 3: Active Lesions, Chronic Sclerotic Lesions, Crescent Formation.
4) By Other Stages: Class 4 (Diffuse Lupus Nephritis), Class 5 (Membranous Lupus Nephritis), Class 6 (Advanced Sclerotic Lupus Nephritis)

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22044&type=smp

What Are The Driving Lupus Nephritis Market Evolution?
The rise in the occurrence of genetic predisposition is projected to drive the expansion of the lupus nephritis market in the future. An individual's inherited genetic traits, which raise their chances of acquiring certain ailments or conditions, are what referred to as genetic predisposition. The growth in genetic predisposition prevalence can be attributed to factors such as inherited traits, environmental impacts, and mutations in designated genes. The rise in the occurrence of genetic predisposition has a crucial influence on the onset of lupus nephritis, accentuating the significance of hereditary genetic factors in autoimmune diseases, specifically those impacting renal function. For instance, the UK CF Registry, a project by the Cystic Fibrosis Trust, reported 11,148 registered patients in 2022, this number rose to 11,318 registered patients in October 2024, indicating a 1.52% growth in cystic fibrosis (CF) individuals. Hence, the rise in the occurrence of genetic predisposition is propelling the expansion of the lupus nephritis market.

Which Firms Dominate The Lupus Nephritis Market Segments?
Major companies operating in the lupus nephritis market are F. Hoffmann-La Roche Ltd., Bristol Myers Squibb, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Genentech, Astrazeneca PLC, Biocon Biologics, Hanmi Pharmaceutical Co. Ltd., Sana Biotechnology Inc., RemeGen Co. Ltd., Aurinia Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Equillium Inc., Anthera Pharmaceuticals Inc., Atara Biotherapeutics Inc., Artiva Biotherapeutics, Caribou Biosciences, Nkarta Inc., Adicet Bio Inc., Lupus Research Alliance, Kyverna Therapeutics Inc., Kezar Life Sciences, Bionxt Solutions.

What Trends Are Expected to Dominate the Lupus Nephritis Market in the Next 5 Years?
A significant concentration of major firms involved in the lupus nephritis market is on the development of improved second-generation calcineurin inhibitors. These efforts aim at amplifying treatment success rates and elevating long-term kidney results for patients. Reduced inflammation and kidney damage prevention via immune response modulation are some of the benefits of these inhibitors within lupus nephritis treatment. For example, in September 2024, the Japanese Ministry of Health, Labour, and Welfare approved Aurinia Pharmaceuticals Inc.'s LUPKYNIS (voclosporin). This Canada-based commercial-stage biopharmaceutical company can now use voclosporin in combination with mycophenolate mofetil (MMF), following data from the AURORA Clinical Program that demonstrated its safety and efficacy. This approval is a considerable progressive step towards broadening lupus nephritis treatment alternatives in Japan, thereby enhancing disease management and outcomes.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/lupus-nephritis-global-market-report

Which Is The Largest Region In The Lupus Nephritis Market?
Asia-Pacific was the largest region in the lupus nephritis market in 2024. The regions covered in the lupus nephritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Lupus Nephritis Market?
2. What is the CAGR expected in the Lupus Nephritis Market?
3. What Are the Key Innovations Transforming the Lupus Nephritis Industry?
4. Which Region Is Leading the Lupus Nephritis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.